Brii-Bio to Hold Virtual AGM on 16 June 2026; Targets 20% Issuance Mandate, 10% Buy-Back and Director Re-elections

Brii Biosciences Limited (Brii-Bio, 02137) has issued its 2026 AGM circular, setting out five key resolutions for shareholder approval at a virtual meeting on 16 June 2026 (08:00 a.m. HKT, via the Vistra eVoting Portal).

Key proposals 1. Financial Statements: Adoption of the audited consolidated results for the year ended 31 December 2025, already reviewed by the Audit and Risk Committee and audited by Deloitte Touche Tohmatsu.

2. Board Composition: Re-election of three directors—Executive Director & CEO Dr Zhi Hong and Independent Non-executive Directors Dr Martin J Murphy Jr and Dr Taiyin Yang. All have offered themselves for re-election.

3. Auditor: Re-appointment of Deloitte Touche Tohmatsu as external auditor for FY 2026, with the Board authorised to fix remuneration.

4. Share Authorities • General Mandate to Issue Shares: Directors seek authority to allot and issue, or dispose of treasury shares, up to 20% of issued share capital (excluding treasury shares) as at the AGM date—equivalent to a maximum of 144.36 million shares, based on the 721.81 million shares in issue as at 20 April 2026. • General Mandate to Buy-Back Shares: Authority to repurchase up to 10% of issued share capital (excluding treasury shares), equating to 72.18 million shares. An additional mandate would extend the issuance limit by the number of shares actually bought back.

Meeting logistics • Format: Virtual-only AGM via Vistra eVoting Portal. • Record date & book closure: Share transfer registration will be suspended from 11 June 2026 to 16 June 2026, both days inclusive. Transfers must be lodged by 4:30 p.m. on 10 June 2026 to qualify for attendance and voting rights. • Proxy deadline: 8:00 a.m. on 14 June 2026. Shareholders may appoint the chairman or another proxy to vote electronically.

Director remuneration • Executive Director Dr Zhi Hong received approximately RMB 12.32 million in FY 2025 and holds or is deemed interested in 43.59 million shares. • Independent Directors Dr Murphy Jr and Dr Yang each receive an annual director’s fee of USD 100,000 and hold 87,000 and 327,000 shares respectively.

The Board recommends shareholders vote in favour of all resolutions at the forthcoming AGM.